Literature DB >> 18245664

Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.

Li Li1, Obdulio Piloto, Ho Bao Nguyen, Kathleen Greenberg, Kogo Takamiya, Frederick Racke, David Huso, Donald Small.   

Abstract

Constitutive activation of FMS-like tyrosine kinase 3 (FLT3) by internal tandem duplication (ITD) mutations is one of the most common molecular alterations known in acute myeloid leukemia (AML). To investigate the role FLT3/ITD mutations play in the development of leukemia, we generated a FLT3/ITD knock-in mouse model by inserting an ITD mutation into the juxtamembrane domain of murine Flt3. FLT3wt/ITD mice developed myeloproliferative disease, characterized by splenomegaly, leukocytosis, and myeloid hypercellularity, which progressed to mortality by 6 to 20 months. Bone marrow (BM) and spleen from FLT3wt/ITD mice had an increased fraction of granulocytes/monocytes and dendritic cells, and a decreased fraction of B-lymphocytes. No sign of acute leukemia was observed over the lifetime of these mice. BM from FLT3wt/ITD mice showed enhanced potential to generate myeloid colonies in vitro. BM from FLT3wt/ITD mice also produced more spleen colonies in the in vivo colony-forming unit (CFU)-spleen assay. In the long-term competitive repopulation assay, BM cells from FLT3wt/ITD mice outgrew the wild-type competitor cells and showed increased myeloid and reduced lymphoid expansion activity. In summary, our data indicate that expression of FLT3/ITD mutations alone is capable of conferring normal hematopoietic stem/progenitor cells (HSPCs) with enhanced myeloid expansion. It also appears to suppress B lymphoid maturation. Additional cooperative events appear to be required to progress to acute leukemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245664      PMCID: PMC2275036          DOI: 10.1182/blood-2007-08-109942

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

Authors:  J E TILL; E A McCULLOCH
Journal:  Radiat Res       Date:  1961-02       Impact factor: 2.841

2.  FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.

Authors:  Jessica A Pollard; Todd A Alonzo; Robert B Gerbing; William G Woods; Beverly J Lange; David A Sweetser; Jerald P Radich; Irwin D Bernstein; Soheil Meshinchi
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

3.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Authors:  H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

4.  Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.

Authors:  Ryoichi Ono; Hideaki Nakajima; Katsutoshi Ozaki; Hidetoshi Kumagai; Toshiyuki Kawashima; Tomohiko Taki; Toshio Kitamura; Yasuhide Hayashi; Tetsuya Nosaka
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

5.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Authors:  Ellen Weisberg; Christina Boulton; Louise M Kelly; Paul Manley; Doriano Fabbro; Thomas Meyer; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

6.  Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells.

Authors:  O Rosnet; C Schiff; M J Pébusque; S Marchetto; C Tonnelle; Y Toiron; F Birg; D Birnbaum
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

7.  Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay.

Authors:  R V Gardner; C Lerner; C M Astle; D E Harrison
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro.

Authors:  L S Rusten; S D Lyman; O P Veiby; S E Jacobsen
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

9.  Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Authors:  Doan T Le; Namie Kong; Yuan Zhu; Jennifer O Lauchle; Abigail Aiyigari; Benjamin S Braun; Endi Wang; Scott C Kogan; Michelle M Le Beau; Luis Parada; Kevin M Shannon
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

10.  Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow.

Authors:  R R Hardy; C E Carmack; S A Shinton; J D Kemp; K Hayakawa
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

View more
  76 in total

Review 1.  FLT3 inhibitors in AML: are we there yet?

Authors:  Akshay Sudhindra; Catherine Choy Smith
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

2.  Disease diversity and FLT3 mutations.

Authors:  Catherine Choy Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

3.  Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia.

Authors:  Anne Kresinsky; Reinhard Bauer; Tina M Schnöder; Tobias Berg; Daria Meyer; Volker Ast; Rainer König; Hubert Serve; Florian H Heidel; Frank-D Böhmer; Jörg P Müller
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

4.  Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.

Authors:  Katherine I Oravecz-Wilson; Steven T Philips; Omer H Yilmaz; Heather M Ames; Lina Li; Brendan D Crawford; Alice M Gauvin; Peter C Lucas; Kajal Sitwala; James R Downing; Sean J Morrison; Theodora S Ross
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

5.  Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice.

Authors:  Li Li; Li Zhang; Jinshui Fan; Kathleen Greenberg; Stephen Desiderio; Feyruz V Rassool; Donald Small
Journal:  Blood       Date:  2011-01-12       Impact factor: 22.113

6.  FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?

Authors:  Mark J Levis; Yi-Bin Chen; Mehdi Hamadani; Mary M Horowitz; Richard J Jones
Journal:  J Clin Oncol       Date:  2019-04-29       Impact factor: 44.544

7.  RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.

Authors:  Ayuna Hattori; Daniel McSkimming; Natarajan Kannan; Takahiro Ito
Journal:  Leuk Res       Date:  2017-01-11       Impact factor: 3.156

8.  miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.

Authors:  Jared A Wallace; Dominique A Kagele; Anna M Eiring; Carissa N Kim; Ruozhen Hu; Marah C Runtsch; Margaret Alexander; Thomas B Huffaker; Soh-Hyun Lee; Ami B Patel; Timothy L Mosbruger; Warren P Voth; Dinesh S Rao; Rodney R Miles; June L Round; Michael W Deininger; Ryan M O'Connell
Journal:  Blood       Date:  2017-04-21       Impact factor: 22.113

9.  In vivo evidence for an instructive role of fms-like tyrosine kinase-3 (FLT3) ligand in hematopoietic development.

Authors:  Panagiotis Tsapogas; Lee Kim Swee; Anja Nusser; Natko Nuber; Matthias Kreuzaler; Giuseppina Capoferri; Hannie Rolink; Rhodri Ceredig; Antonius Rolink
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

Review 10.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.